FDA approves blinatumomab for MRD-positive acute lymphoblastic leukemia
eMediNexus, 30 March 2018
remove_red_eye 1467 Views
#Hematology #Nursing #Oncology #Pathology and Lab Medicine
remove_red_eye 1467 Views
#Hematology #Nursing #Oncology #Pathology and Lab Medicine
The US FDA has expanded the approval of blinatumomab (Blincyto) to include the treatment of B-cell precursor acute lymphoblastic leukemia (ALL), for patients in remission who still have minimal residual disease (MRD).
To continue reading this article
Sign in with Medtalks
Sign in with Facebook
Continue reading your article with a eMediNexus account.
Free Membership!
